ClinicalTrials.gg
CompletedNCT02682264Updated Nov 17, 2020Results posted

An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris

A Phase 3 interventional study of CB-03-01 cream, 1% in Acne Vulgaris, sponsored by Cassiopea SpA. Completed at 74 sites in 7 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2020-11-17.

Sponsored by Cassiopea SpA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
609
Allocation
Not applicable
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
5th of 19
609 · median 50
Started
2016
with 2 others
Phase 3
5 of 19
2 open now
Registered
5th of 19
by date
Lead sponsor
4 of 19
Cassiopea SpA

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 5th largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 5th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the long-term safety of CB-03-01 cream, 1% applied twice daily for an additional nine months in study participants with acne vulgaris that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months.

Read the detailed description

This was a multicenter, open label, long-term extension study for CB-03-01 cream, 1% focused on safety in male and female participants, 9 years or older who completed one of the Phase 3 pivotal studies [CB-03-01/25 and CB-03-01/26]. Participants applies the active medication (CB-03-01 cream, 1%) twice daily to the entire face and, if designated by investigator AND desired by the participant, truncal acne for nine additional months of treatment. Thus, overall participants were exposed to CB-03-01 cream, 1% for a total treatment of up to 12 months (0 or 3 months in the Phase 3 pivotal study and an additional nine months in this long-term safety study).

Participants treated facial acne per protocol for nine months. Treatment of truncal acne was discussed by the investigator and participant. Treatment on the face and/or trunk was discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area (i.e., face and trunk).

Participants were rolled over from the Phase 3 pivotal studies [CB-03-01/25 and CB-03-01/26] into this long-term, safety study in order to achieve at least 300 participants on-study at 6 months and 100 participants on-study at 12 months.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne
  • clascoterone
  • anti-androgen
04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has successfully completed participation in one of the Phase 3 pivotal studies [CB-03-01/25 and CB-03-01/26].
  • Participant agrees to use effective method of throughout study, if applicable.
  • Participant has provided written or assent.
  • Participant is willing to comply with study instructions and return to the clinic for required visits.

Exclusion criteria

Exclusion Criteria:

  • Participant is pregnant, lactating, or is planning to become pregnant during the study.
  • Participant has any skin disease or condition that could interfere with the safety evaluation of the test products or requires the use of interfering topical or systemic therapy.
  • Participant has any condition which, in the investigator's opinion, would make it unsafe or unsuitable for the participant to participate in this research study.
  • Participant plans to use any other drug or device during participation in this study.
  • Participant has known or previous allergic reaction to the drug or any of its ingredients.
  • Participant is or plans to use any restricted systemic and/or topical anti-acne preparations or medications during the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
609 participants (actual)

Study arms

  • Experimental
    CB-03-01 cream, 1%

    CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.

    Drug: CB-03-01 cream, 1%

Interventions

  • Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.

    Also known as: cortexolone 17α-propionate, clascoterone (USAN, INN)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Local and Systemic Treatment Emergent Adverse Events

    Number of participants with any local and systemic treatment emergent AEs (TEAEs)

    Time frame: up to 52 weeks

07

Results

Posted Nov 17, 2020

Participant flow

There were 609 subjects who were rolled over (i.e., enrolled) from the two Phase 3 pivotal studies (CB-03-01/25 \[NCT02608450\] and CB-03-01/26 \[NCT02608476\]) into this long-term, safety study. However, two (2) subjects in the original vehicle cream were not treated with test article and thus were excluded from the study population (Safety set).

Participant flow — Overall Study
MilestoneCB-03-01 Cream, 1%CB-03-01 Cream, 1% (Vehicle Arm)
Started317290
Completed179168
Not completed138122
Withdrew: Withdrawal by subject5645
Withdrew: Lost to follow-up4941
Withdrew: Lack of efficacy1416
Withdrew: Withdrawal by parent67
Withdrew: Adverse event90
Withdrew: Noncompliance with study drug14
Withdrew: Pregnancy12
Withdrew: Recovery12
Withdrew: Progressive disease10
Withdrew: Technical problems01
Withdrew: Moved abroad and unable to continue03
Withdrew: Stopped test article application01

Outcome measures

PrimaryNumber of Participants With Any Local and Systemic Treatment Emergent Adverse Events

Number of participants with any local and systemic treatment emergent AEs (TEAEs)

Time frame:
up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Local and Systemic Treatment Emergent Adverse Events
ParticipantsCB-03-01 Cream, 1%CB-03-01 Cream, 1% (Vehicle Arm)
Number of Participants With Any Local and Systemic Treatment Emergent Adverse Events5852

Adverse events

Collected over Treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) were collected from the time the subject exited the pivotal study (i.e., Week 13 or day 1 of the Long-term extension study) and up to 52 weeks after entry into the pivotal study (i.e., up to week 39 or early termination of the long term extension study).. Non-serious events are listed at a 0.7% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CB-03-01 Cream, 1%0/317 (0%)3/317 (0.9%)21/317 (6.6%)
CB-03-01 Cream, 1% (Vehicle Arm)0/290 (0%)3/290 (1%)17/290 (5.9%)
Most frequent serious events
Most frequent serious events
EventCB-03-01 Cream, 1%CB-03-01 Cream, 1% (Vehicle Arm)
FatigueGeneral disorders0/3171/290
Abortion inducedSurgical and medical procedures0/3171/290
Coronary artery dissectionVascular disorders0/3171/290
DepressionPsychiatric disorders1/3170/290
Suicide attemptPsychiatric disorders1/3170/290
Gastroenteritis eosinophilicGastrointestinal disorders1/3170/290
DizzinessNervous system disorders1/3170/290
Most frequent other events
Most frequent other events
EventCB-03-01 Cream, 1%CB-03-01 Cream, 1% (Vehicle Arm)
NasopharyngitisInfections and infestations6/31710/290
Upper respiratory tract infectionInfections and infestations7/3171/290
Respiratory tract infection viralInfections and infestations1/3174/290
Application site acneGeneral disorders4/3170/290
SinusitisInfections and infestations3/3172/290

Baseline characteristics

Safety population defined as all subjects who applied at least one dose of test article.

Age, Continuous
Age, Continuous(years)CB-03-01 Cream, 1%CB-03-01 Cream, 1% (Vehicle Arm)Total
Mean19.2 ± 5.819.3 ± 6.719.2 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)CB-03-01 Cream, 1%CB-03-01 Cream, 1% (Vehicle Arm)Total
Female198183381
Male119107226
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CB-03-01 Cream, 1%CB-03-01 Cream, 1% (Vehicle Arm)Total
Hispanic or Latino271542
Not Hispanic or Latino290275565
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CB-03-01 Cream, 1%CB-03-01 Cream, 1% (Vehicle Arm)Total
American Indian or Alaska Native101
Asian6814
Native Hawaiian or Other Pacific Islander213
Black or African American171835
White283256539
More than one race4610
Unknown or Not Reported415
08

Study locations

74 sites
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • Gary M. Petrus, MD PA
    Little Rock, Arkansas 72205, United States
  • Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • Rady Childrens Hospital, Pediatric and Adolescent Dermatology
    San Diego, California 92123, United States
  • Southern California Dermatology
    Santa Ana, California 92701, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Memorial Research Medical Clinic dba / Orange County Research Center
    Tustin, California 92780, United States
  • Horizons Clinical Research Center, LLC
    Denver, Colorado 80220, United States
  • Study Protocol, Inc.
    Boynton Beach, Florida 33437, United States
  • Tory Sullivan, M.D., P.A.
    North Miami Beach, Florida 33162, United States
  • Belleair Research Center
    Pinellas Park, Florida 33781, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • MOORE Clinical Research, Inc.
    Tampa, Florida 33609, United States
  • MedaPhase, Inc.
    Newnan, Georgia 30263, United States
  • Arlington Dermatology
    Arlington Heights, Illinois 60005, United States
  • Shideler Clinical Research Center
    Carmel, Indiana 46032, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Kansas City Dermatology, PA
    Overland Park, Kansas 66215, United States
  • Maryland Laser Skin and Vein Institute
    Hunt Valley, Maryland 21030, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Sadick Research Group, LLC
    New York, New York 10075, United States
  • Skin Specialty Dermatology
    New York, New York 10155, United States
  • DermResearch Center of New York, Inc.
    Stony Brook, New York 11790, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • The Pennsylvania State University and the Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Greenville Dermatology, LLC
    Greenville, South Carolina 29607, United States
  • International Clinical Research - Tennessee LLC
    Murfreesboro, Tennessee 37130, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Westlake Dermatology Clinical Research Center
    Austin, Texas 78746, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Austin Institute for Clinical Research, Inc.
    Pflugerville, Texas 78660, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Progressive Clinical Research, PA
    San Antonio, Texas 78229, United States
  • Clinical Research Associates of Tidewater, Inc.
    Norfolk, Virginia 23507, United States
  • Dermatology Associates
    Seattle, Washington 98101, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
  • Site 3521
    Plovdiv, 4000, Bulgaria
  • 3520
    Sofia, 1407, Bulgaria
  • Site 3524
    Sofia, 1407, Bulgaria
  • Site 3519
    Sofia, 1431, Bulgaria
  • Site 3526
    Sofia, 1618, Bulgaria
  • Site 3522
    Varna, 9010, Bulgaria
  • Site 9912
    Tbilisi, 0114, Georgia
  • Site 9911
    Tbilisi, 0159, Georgia
  • Site 9913
    Tbilisi, 9913, Georgia
  • Site 4814
    Białystok, Poland
  • 4819
    Bydgoszcz, Poland
  • Site 4822
    Czestochowa, Poland
  • Site 4811
    Dąbrówka, Poland
  • 4815
    Katowice, Poland
  • Site 4821
    Kraków, Poland
  • Site 4823
    Osielsko, Poland
  • Site 4813
    Szczecin, Poland
  • Site 4818
    Warszawa, Poland
  • Site 4812
    Wrocław, Poland
  • Site 4820
    Łódź, Poland
  • Site 4033
    Sector 2, Bucharest 020125, Romania
  • Site 4034
    Sector 2, Bucharest 020125, Romania
  • Site 4031
    Sector 3, Bucharest 030303, Romania
  • Site 4029
    Sector 6, Bucharest 062272, Romania
  • Site 4028
    Târgovişte, Jud. Dambovita, Romania
  • Site 4035
    Bucharest, Romania
  • Site 4037
    Iaşi, 700381, Romania
  • Site 4030
    Sibiu, Romania
  • Site 8138
    Belgrade, 11050, Serbia
  • Site 8137
    Belgrade, 8137, Serbia
  • Site 8136
    Novi Sad, 21000, Serbia
  • Site 3802
    Dnipro, 49000, Ukraine
  • Site 3808
    Kharkiv, 61002, Ukraine
  • Site 3804
    Kharkiv, 61038, Ukraine
  • Site 3809
    Zaporizhzhya, 69063, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Aug 2018, 29 months.

Results were first posted in Nov 2020, 2 years 2 months after primary completion. A results delay was requested in Jun 2019.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 29 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2016
First posted
Feb 15, 2016
StartActual
Mar 9, 2016
Primary completionActual
Aug 31, 2018
CompletionActual
Aug 31, 2018
Results delay requested
Jun 7, 2019
Results first posted
Nov 17, 2020
Last update
Nov 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02682264
Lead sponsor
Cassiopea SpA
Responsible party
Sponsor
First posted
Feb 15, 2016
Start date
Mar 9, 2016
Primary completion
Aug 31, 2018
Completion
Aug 31, 2018
Results posted
Nov 17, 2020
Last update
Nov 17, 2020

Study contacts

R&D Cassiopea
study director · Cassiopea SpA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion